South San Francisco, CA, United States of America

Michael FT Koehler

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Genentech, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael FT Koehler. Retrieved from https://idiyas.com/inventor/michael-ft-koehler-gxym0v1g

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael FT Koehler: A Visionary in Medical Research

Introduction

Michael FT Koehler is a notable inventor and researcher based in Palo Alto, California. He has made significant contributions to the field of medical research, particularly through his work at prominent institutions. Although he holds no patents, his influence in the industry is recognized through his professional affiliations.

Latest Patents

Michael FT Koehler currently has 1 patents. Despite this, his work has been impactful in advancing medical research methodologies.

Career Highlights

Throughout his career, Koehler has worked with esteemed organizations such as Genentech, Inc. and the Walter and Eliza Hall Institute of Medical Research. His experience in these institutions has allowed him to contribute to groundbreaking research and development in the medical field.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Michael FT Koehler's career reflects a commitment to advancing medical research, even in the absence of patents. His work at leading institutions showcases his dedication to innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…